Sotigalimab (** Generic (investigational) **)
Immunotherapy
Description
Sotigalimab is under investigation for the treatment of metastatic colorectal cancer, particularly in patients with mismatch repair deficient tumors or those who have progressed on other immunotherapy agents; its efficacy and safety are currently being evaluated in clinical trials. It may be used as a single agent or in combination with chemotherapy.
Mechanism of Action
Sotigalimab is a humanized monoclonal antibody that targets the programmed death-ligand 1 (PD-L1) protein, blocking its interaction with PD-1 and B7.1 receptors to inhibit tumor cell proliferation.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | ** Generic (investigational) ** |
| Category | Immunotherapy |
 EMA Status | Experimental |
 Spain Access | Not available |
| Clinical Trials | 1 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.